Effects of omalizumab therapy on peripheral nerve functions: short observational study


YAVUZ G., YıLGÖR A., Yavuz I., MILANLıOĞLU A., ÇILINGIR V., ÇAĞAÇ A., ...More

POSTEPY DERMATOLOGII I ALERGOLOGII, vol.36, no.2, pp.211-216, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.5114/ada.2018.74834
  • Journal Name: POSTEPY DERMATOLOGII I ALERGOLOGII
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.211-216
  • Keywords: chronic urticaria, omalizumab, neuropathy, INFLAMMATORY DEMYELINATING POLYNEUROPATHY, SAFETY, TOLERABILITY, NEUROPATHY, URTICARIA, DIAGNOSIS, PATIENT

Abstract

Introduction: Peripheral neuropathy (PN) is a common neurological condition causing symmetrical and diffuse damage in nerves. The etiology of PN includes systemic diseases, toxic exposure, medications, infections, and hereditary diseases. Omalizumab is a humanized monoclonal anti-IgE antibody that exerts its activity by binding to free IgE in circulation.